Select display options below. (Cookies need to be enabled in your browser!)
Colors: High contrast    Default    Font Size: X-Large    Large    Medium    Default    Small   
 
 
Research & Clinical Trials

Study Detail: Lucentis and Psychological morbidity in Retinal Vein Occlusion

Trial Description Summary : To study the psychological impact of vein occlusions. There will be two groups. One group of patients, with active disease, will be treated with Lucentis for 6 months and answer questionnaires. The second group, with inactive disease, will just complete questionniares.

Basic Trial Information
Phase: III
Disease:Vein Occlusion (either central retinal or branch)
Sponsor: Genentech
Protocol Number: FVF4638s
Status: Enrolling

Study Duration: 6 months   

Eligibility Criteria:
   Inclusion Criteria
         CRVO in all 4 quadrants with dilated veins OR BRVO on clinical exam
         BCVA 20/40-20/8,000 inclusive
         OCT greater than, or equal to, 250 microns
         No previous treatment that might compromise or confound assessment of the study outcomes

    Exclusion Criteria
          History of any laser in study eye
          History of vitreal surgery
          Previous treatment (either eye) with
                           triamcinolone
                           bevacizumab
                           pegaptabnib
                           ranibizumab
         CVA less that 1 year before study enrollment
    
The above inclusion/exclusion criteria is not complete and the study coordinator will do a complete screening.

Study Title : Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion

Trial Contact Information
Site: Beachwood 
Study Coordinator: Dianne H 216/831-5704 extension 253